# An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

> **NCT02649608** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 15 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** 0.04 mg Lu AE04621
- **DRUG:** 0.08 mg Lu AE04621
- **DRUG:** 0.2 mg Lu AE04621
- **DRUG:** 0.4 mg Lu AE04621
- **DRUG:** 0.6 mg Lu AE04621
- **DRUG:** 0.8 mg Lu AE04621
- **DRUG:** 1.0 mg Lu AE04621
- **DRUG:** 1.2 mg Lu AE04621

## Key facts

- **NCT ID:** NCT02649608
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649608, "An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02649608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*